Stocks and InvestingStocks and Investing
Thu, October 5, 2017
Wed, October 4, 2017
Tue, October 3, 2017
Mon, October 2, 2017
Fri, September 29, 2017
Thu, September 28, 2017
Wed, September 27, 2017
Tue, September 26, 2017
Mon, September 25, 2017
Fri, September 22, 2017

Do Kim Maintained (ALNY) at Buy with Increased Target to $134 on, Sep 22nd, 2017


Published on 2024-10-25 22:58:31 - WOPRAI, Do Kim
  Print publication without navigation


Do Kim of BMO Capital, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Increased Target from $99 to $134 on, Sep 22nd, 2017.

Do has made no other calls on ALNY in the last 4 months.



There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 2 agree with Do's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $101 on, Thursday, September 21st, 2017
  • Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $112 on, Thursday, September 21st, 2017


These are the ratings of the 4 analyists that currently disagree with Do


  • Alan Carr of "Needham" Maintained at Strong Buy with Increased Target to $125 on, Thursday, September 21st, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $123 on, Thursday, September 21st, 2017
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $127 on, Thursday, September 21st, 2017
  • Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017